Ocular Therapeutix (OCUL) Operating Leases (2019 - 2026)

Ocular Therapeutix has reported Operating Leases for 8 years, with the latest figure at $4.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 13.07% year-over-year to $4.2 million; the trailing twelve-month figure through Mar 2026 stood at $4.2 million (down 13.07% YoY), and the FY2025 full-year result was $2.8 million, down 47.33% from the prior year.
• Operating Leases for Q1 2026 stood at $4.2 million, up from $2.8 million in the prior quarter.
• The five-year high for Operating Leases was $8.7 million in Q4 2022, with the low at $2.8 million in Q4 2025.
• Average Operating Leases over 5 years is $5.7 million, with a median of $5.5 million recorded in 2022.
• Year-over-year, Operating Leases jumped 57.29% in 2023 and tumbled 47.33% in 2025.
• Tracing OCUL's Operating Leases over 5 years: stood at $8.7 million in 2022, then decreased by 20.74% to $6.9 million in 2023, then dropped by 22.29% to $5.3 million in 2024, then plunged by 47.33% to $2.8 million in 2025, then jumped by 50.27% to $4.2 million in 2026.
• The last three Operating Leases figures came in at $4.2 million (Q1 2026), $2.8 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.

Peer Comparison